Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

<p>Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [<a href="/article/info:doi/10.1371/journal.pgph.0004281#pgph.0004281.ref014" target="_blank">14</a>,<a href="/article/info:doi/10.1371/journal.pgph....

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Seyed Reza Mousavi (13223324) (author)
Інші автори:	Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author)
Опубліковано:	2025
Предмети:	Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
за авторством: Anna Starshinova (22571846)
Опубліковано: (2025)

Supplementary Materials: Propagation of Beta bursts from the motor cortex to the motor units of multiple upper-limb muscles
за авторством: Shlomi Haar (7537199)
Опубліковано: (2025)

Factors associated with EMG improvement after 6 months of follow-up of the uremic neuropathy in patients having a pathological first EMG.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Association between polyneuropathy presence and clinical/biological features during initial EMG in a 31-patient cohort.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Evolution of EMG parameters between first and second EMG among children having an End Stage Kidney Disease with an Uremic neuropathy (n = 24).
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Evolution of the pathological EMG in dialysis and no-dialysis group.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Comparison of electrophysiological abnormalities between pre-dialysis and dialysis Groups among children (n = 31) having an End Stage Kidney Disease.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Comparison between pre-dialysis and dialysis groups regarding clinical features and biological findings.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Comparison of Severity Grade and Normal EMG Between First and Second EMG Assessments in dialysis group at T2.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Participants’ follow-up between T1 and T2.
за авторством: Arwa Yahyaoui (22683276)
Опубліковано: (2025)

Figure 6 – Source Data and MATLAB Code (dmPFC firing, neural selectivity, and LDA decoding)
за авторством: Jinseon Yu (22598699)
Опубліковано: (2025)

Supplementary file 2_Navigating barriers and facilitators to lifestyle changes after bariatric surgery among Emirati adolescents: a qualitative study.pdf
за авторством: Baraa A. Alries (22687031)
Опубліковано: (2025)

Supplementary file 1_Navigating barriers and facilitators to lifestyle changes after bariatric surgery among Emirati adolescents: a qualitative study.docx
за авторством: Baraa A. Alries (22687031)
Опубліковано: (2025)

Figure 5 – Source Data (chemogenetic activation of TF synapses and behavioral rescue)
за авторством: Jinseon Yu (22598699)
Опубліковано: (2025)

Table 1_Development and validation of a nomogram-based prediction model for hospital-acquired carbapenem-resistant Acinetobacter baumannii in critically ill patients: a multicenter retrospective cohort study.docx
за авторством: Wenjing Jiang (7436471)
Опубліковано: (2025)

Table 2_Development and validation of a nomogram-based prediction model for hospital-acquired carbapenem-resistant Acinetobacter baumannii in critically ill patients: a multicenter retrospective cohort study.docx
за авторством: Wenjing Jiang (7436471)
Опубліковано: (2025)

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
за авторством: Naohiro Wakisaka (407153)
Опубліковано: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
за авторством: Naohiro Wakisaka (407153)
Опубліковано: (2025)

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
за авторством: Naohiro Wakisaka (407153)
Опубліковано: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
за авторством: Naohiro Wakisaka (407153)
Опубліковано: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
за авторством: Naohiro Wakisaka (407153)
Опубліковано: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
за авторством: Naohiro Wakisaka (407153)
Опубліковано: (2025)

Regio-Dependent Optoelectronic Properties of Oligomeric Peropyrenes
за авторством: Haruki Sanematsu (21464607)
Опубліковано: (2025)

Microbiome Mediated Immune Crosstalk on the Gut-Thyroid Axis in Autoimmune Thyroid Disease
за авторством: Mubeen Hussein Arawker (12965954)
Опубліковано: (2025)

Prevalence and detection rates of prespecified fetal anomalies <16 weeks gestational age according to first-trimester anatomy screening policy.
за авторством: Jehan N. Karim (22683195)
Опубліковано: (2025)

Early detection of 14 fetal congenital anomalies based on the type of first-trimester anatomical screening policy.
за авторством: Jehan N. Karim (22683195)
Опубліковано: (2025)

Response rates of trusts by regions as defined by Public Health England (PHE) at time of study.
за авторством: Jehan N. Karim (22683195)
Опубліковано: (2025)

Survey of dysphagia protocol use (Carnaby et al., 2025)
за авторством: Giselle D. Carnaby (22575401)
Опубліковано: (2025)

Comparison of hierarchical classifier performance among four machine learning models for the early-loss, intermediate-loss, and late/no-loss groups.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of multi-class classifier performance among four machine learning models for early-loss, intermediate-loss, and late/no-loss groups.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of binary classifier performance among four machine learning models for early-loss, intermediate-loss, and late/no-loss groups.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of performance of four machine learning models for long-term graft loss prediction.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of prediction performance with previously reported metrics.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of performance of four machine learning models for early graft loss prediction.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Predicting stratified groups in the validation cohort: (A) Workflows for the multi-class classification and hierarchical classification models are illustrated.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Stratification and characterization of groups showing different graft survival: (A) UMAP visualization of the stratified derivation cohort data based on the distance matrix from the RF clustering.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_64vtcugunae8b9tfr9hold4mvi